Blog

We tested the publicly available AlphaFold 3 instance and have reviewed the paper. Note that access to the full tool is not yet available and is provided only as a server with limitations. Here's what we found.

The third part in our series on the challenges and opportunities of computational drug discovery. We detail what we've been working on.

What are the key challenges in docking and virtual screening? And what we're doing to combat them.

The biotech landscape is littered with the graves of projects and companies that picked the wrong molecule, and researchers have dedicated considerable resources to solving it.

Buckle up, because we’re about to embark on a journey into the future of life sciences - the merger of Deep Origin and BiosimAI. The strategic fusion of these two entities amplifies their capabilities, combining BiosimAI’s molecular simulation capabilities with Deep Origin’s computational infrastructure to enable R&D at unprecedented accuracy, scale, and speed. As part of the merger, BiosimAI's tools will become available for users in Deep Origin's computational platform, democratizing access to molecular simulation. Long-term, the merger will enable BiosimAI and Deep Origin to work together to develop predictive simulations of living systems that can accelerate drug development and ultimately help humanity live longer, healthier, and happier lives.